差别PCR技术检测卵巢癌c-erbB-2癌基因扩增的研究  

Study on Differential Polymerase Chain Reaction of c-erbB-2 Oncogene Amplification in Ovarian Carcinoma

作　　者：张竹强[1] 岳秀兰[1] 曹虹然[2] 白雪峰[2] 

机构地区：[1]包头医学院生物化学教研室,内蒙古包头014010 [2]包头市第七医院

出　　处：《包头医学院学报》2007年第3期229-233,共5页Journal of Baotou Medical College

基　　金：内蒙古自然科学基金;批准号:200308020611

摘　　要：目的:探讨卵巢癌c-erbB-2癌基因扩增的临床意义。方法:应用差别PCR技术检测36例原发性卵巢癌c-erbB-2癌基因的扩增情况。结果:(1)卵巢癌组织中c-erbB-2癌基因的扩增率为58.3%(21/36);(2)肿块≥5 cm的卵巢癌组织及中晚期卵巢癌患者c-erbB-2癌基因扩增率分别为67.9%、73.9%,明显高于肿块<5 cm的卵巢癌组织25.0%的扩增率和早期卵巢癌患者30.8%的扩增率,均有显著差异(P<0.05);(3)卵巢癌组织中c-erbB-2癌基因扩增与患者年龄、病理类型、淋巴转移、雌激素受体(ER)及孕激素受体(PR)无相关性。结论:c-erbB-2癌基因扩增与卵巢癌的发生有一定关系,c-erbB-2癌基因扩增对卵巢癌的治疗、预后判断具有重要的临床应用意义。Objective： To explore the clinical significance of c - erbB - 2 oncogene amplification in ovarian carcinoma. Methods： c - erbB - 2 oncogene amplification was examined by using differential polymerase chain reation in 36 cases of ovarian carcinoma. Results ： （ 1 ） c - erbB - 2 amplification was found in 58.3 % （21/36） of ovarian carcinoma. （2） The positive expression rate of c - erbB - 2 in patients with ≥5cm tumor size and in the late stage was 67.9% and 73.9%, respectively, higher than that in those with 〈 5cm tumor size （25.0%）and in the early stage（ 30.8% ）. （3）c -erbB -2 oncogene amplification was not correlated to the age,pathhological patterns, lymphatic transfer, estrogen receptor（ER） and progestogen receptor（PR）. Conclusion： The results suggest that c -erbB -2 amplification plays a role in the process of ovarian carcinoma and may be one of those significant prognostic factors for treating and predicting prognosis of ovarian carcinoma.

关 键 词：卵巢癌 C-ERBB-2 差别PCR 癌基因扩增 

分 类 号：R737.31[医药卫生—肿瘤]